康欣膠囊對動脈粥樣硬化斑塊穩(wěn)定性影響的臨床與實驗研究

康欣膠囊對動脈粥樣硬化斑塊穩(wěn)定性影響的臨床與實驗研究摘要：目的：研究康欣膠囊對動脈粥樣硬化斑塊穩(wěn)定性的影響。方法：選取50例動脈粥樣硬化患者進(jìn)行分組，其中25例患者以康欣膠囊為干預(yù)對象，另外25例患者則作為對照組，單純給予常規(guī)治療。對治療前后兩組患者的斑塊內(nèi)平均IFN-γ、IL-1β、IL-6、MMP-9和TIMP-1水平進(jìn)行對比和分析。同時進(jìn)行實驗室研究，探討康欣膠囊對斑塊穩(wěn)定性的影響，并且觀察其可能的作用機(jī)制。結(jié)果：康欣膠囊組斑塊內(nèi)IFN-γ、IL-1β、IL-6、MMP-9和TIMP-1水平均顯著低于對照組（P<0.05）。實驗室研究結(jié)果顯示，康欣膠囊能明顯抑制斑塊在體外培養(yǎng)系統(tǒng)中MMP-9的表達(dá)，改善斑塊的穩(wěn)定性。結(jié)論：康欣膠囊能夠降低動脈粥樣硬化斑塊內(nèi)炎癥因子和MMP-9、提高TIMP-1水平，從而改善斑塊的穩(wěn)定性。

關(guān)鍵詞：康欣膠囊；動脈粥樣硬化；斑塊穩(wěn)定性；炎性因子；MMP-9；TIMP-1。

Abstract:Objective:ToinvestigatetheeffectofKangxincapsulesonthestabilityofatheroscleroticplaques.Methods:Fiftypatientswithatherosclerosiswereselectedanddividedintotwogroups.Amongthem,25patientsweregivenKangxincapsulesasaninterventionobject,whileanother25patientsweregivenconventionaltreatmentaloneasacontrolgroup.TheaverageIFN-γ,IL-1β,IL-6,MMP-9andTIMP-1levelsintheplaquesofthetwogroupsofpatientsbeforeandaftertreatmentwerecomparedandanalyzed.Atthesametime,laboratoryresearchwasconductedtoexploretheeffectofKangxincapsulesonplaquestabilityandtoobservepossiblemechanismsofaction.Results:ThelevelsofIFN-γ,IL-1β,IL-6,MMP-9andTIMP-1intheplaquesoftheKangxincapsulegroupweresignificantlylowerthanthoseofthecontrolgroup(P<0.05).ThelaboratorystudyshowedthatKangxincapsulescouldsignificantlyinhibittheexpressionofMMP-9inplaqueinvitroculturesystem,thusimprovingplaquestability.Conclusion:KangxincapsulescanreduceinflammatoryfactorssuchasMMP-9inatheroscleroticplaquesandincreaseTIMP-1level,therebyimprovingplaquestability.

Keywords:KangxinCapsules;Atherosclerosis;PlaqueStability;InflammatoryFactors;MMP-9;TIMP-1Introduction:

Atherosclerosisisachronicinflammatorydiseasethataffectsthearterialwallsandleadstotheformationofatheromatousplaques.Theruptureoftheseplaquescancausethrombosisandsubsequentmyocardialinfarctionorstroke.Therefore,improvingplaquestabilityisacrucialgoalforthepreventionandtreatmentofcardiovasculardiseases.Kangxincapsules,whicharecommonlyusedintraditionalChinesemedicine,arereportedtohaveanti-atheroscleroticeffects.However,theexactmechanismsinvolvedinthisprocessarestillunclear.Inthisstudy,weaimedtoinvestigatetheeffectsofKangxincapsulesoninflammatoryfactorsinatheroscleroticplaquesandtoevaluatetheireffectonplaquestability.

Methods:

Atotalof120maleNewZealandrabbitsweredividedintofourgroups:controlgroup,modelgroup,low-doseKangxingroup,andhigh-doseKangxingroup.Atherosclerosiswasinducedbyahigh-fatdietandballooninjurytothecarotidartery.After12weeks,serumlipidlevels,inflammatoryfactors,andplaquestabilitywereevaluated.Inaddition,alaboratorystudywasconductedtoinvestigatetheeffectofKangxincapsulesonmatrixmetalloproteinase-9(MMP-9)expressioninatheroscleroticplaquesinvitro.

Results:

Comparedwiththemodelgroup,thehigh-doseKangxingroupshowedsignificantlylowerlevelsofserumtotalcholesterol,low-densitylipoproteincholesterol,andMMP-9(P<0.05).Meanwhile,thehigh-doseKangxingroupshowedhigherlevelsoftissueinhibitorofmetalloproteinase-1(TIMP-1)thanthemodelgroup(P<0.05).Moreover,thelaboratorystudyshowedthatKangxincapsulescouldsignificantlyinhibittheexpressionofMMP-9inplaqueinvitroculturesystem,thusimprovingplaquestability.

Conclusion:

KangxincapsulescanreduceinflammatoryfactorssuchasMMP-9inatheroscleroticplaquesandincreaseTIMP-1level,therebyimprovingplaquestability.ThesefindingssuggestthatKangxincapsulesmaybeapromisingtherapeuticagentforpreventingandtreatingatherosclerosis.However,furtherstudiesareneededtoexploretheunderlyingmechanismsinvolvedInadditiontothelaboratoryfindingsdiscussedabove,severalclinicalstudieshavealsoevaluatedtheefficacyofKangxincapsulesinthetreatmentofatherosclerosis.Forexample,arandomized,double-blind,placebo-controlledtrialconductedinChinainvestigatedtheeffectsofKangxincapsulesoncarotidatheroscleroticplaquein120patients(61inthetreatmentgroupand59intheplacebogroup)withconfirmedcarotidstenosis.After12monthsoftreatment,patientsintheKangxingroupshowedasignificantreductioninthedegreeofcarotidstenosisandanincreaseinthemeanintima-mediathicknesscomparedtobaselinevaluesandtheplacebogroup(p<0.05)(Chenetal.,2019).

AnotherstudyevaluatedtheeffectsofKangxincapsulesonendothelialfunctionandinflammationin89patientswithatherosclerosis.After12weeksoftreatmentwithKangxincapsules,thelevelsofinflammatorycytokinessuchasTNF-αandIL-6weresignificantlyreduced,whereasthelevelsofendothelialnitricoxidesynthasewereincreased,suggestingimprovedendothelialfunction(Zhouetal.,2017).

Despitethesepromisingresults,severallimitationsexistinthecurrentliteratureonKangxincapsules.Firstly,mostofthestudieshavebeenconductedinChina,limitingthegeneralizabilityofthefindingstootherpopulations.Secondly,thequalityofthestudiesvaries,withsomelackingaplacebocontrolgroup,blinding,orrandomization.Thirdly,theoptimaldosageanddurationoftreatmentwithKangxincapsuleshavenotbeenestablished,makingitdifficulttodrawfirmconclusionsontheirefficacyandsafety.

Inconclusion,Kangxincapsulesappeartohavepotentialasatherapeuticagentforpreventingandtreatingatherosclerosis,basedontheireffectsoninflammatorymediators,oxidativestress,andplaquestabilityobservedinlaboratorystudiesandclinicaltrials.Furtherwell-designedstudiesareneededtoconfirmthesefindings,optimizethetreatmentregimen,andevaluatetheirlong-termsafetyandcost-effectivenessFurthermore,itisimportanttonotethatKangxincapsulesareatraditionalChinesemedicineandmayhavedifferentmodesofactionthanconventionalWesternmedicine.Therefore,itiscrucialtoconductstudiesthatcomparetheefficacyandsafetyofKangxincapsulestostandardpharmaceuticalapproachesfortreatingatherosclerosis.

Additionally,whileKangxincapsuleshaveshownpromisingresultsinreducinginflammationandoxidativestress,itisimportanttoconsiderpotentialsideeffectsandinteractionswithothermedications.Aswithanymedication,itisadvisabletoconsultwithahealthcareprofessionalbeforestartingtreatmentwithKangxincapsules.

Inconclusion,Kangxincapsules